東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Pathogenesis of systemic lupus eryth...

Hoi, Alberta.

FindBook

Google Book

Amazon

博客來

Pathogenesis of systemic lupus erythematosus = insights from translational research /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Pathogenesis of systemic lupus erythematosus/ edited by Alberta Hoi.
其他題名:	insights from translational research /
其他作者:	Hoi, Alberta.
出版者:	Cham :Springer International Publishing : : 2021.,
面頁冊數:	xxi, 178 p. :ill., digital ;24 cm.
內容註:	Advances in translational science to identify new therapies for systemic lupus erythematosus -- Hallmark of systemic lupus erythematosus: Role of B Cell Hyperactivity. Fabien B Vincent, William A Figgett and Margaret L Hibbs -- B cell targeted therapies in systemic lupus erythematosus -- Type I Interferons and the perpetuation of a loss of tolerance -- Therapeutic Modulation of the Interferon Pathway in Systemic Lupus Erythematosus -- The concept of co-stimulatory blockade in SLE -- Cytokines: their role in amplifying SLE pathogenesis -- Intracellular targets in SLE -- Regulatory T cells in SLE -- Balancing strategies: GC and GILZ Axis.
Contained By:	Springer Nature eBook
標題:	Systemic lupus erythematosus - Pathogenesis. -
電子資源:	https://doi.org/10.1007/978-3-030-85161-3
ISBN:	9783030851613

Pathogenesis of systemic lupus erythematosus = insights from translational research /
Pathogenesis of systemic lupus erythematosusinsights from translational research /[electronic resource] :edited by Alberta Hoi. - Cham :Springer International Publishing :2021. - xxi, 178 p. :ill., digital ;24 cm.

Advances in translational science to identify new therapies for systemic lupus erythematosus -- Hallmark of systemic lupus erythematosus: Role of B Cell Hyperactivity. Fabien B Vincent, William A Figgett and Margaret L Hibbs -- B cell targeted therapies in systemic lupus erythematosus -- Type I Interferons and the perpetuation of a loss of tolerance -- Therapeutic Modulation of the Interferon Pathway in Systemic Lupus Erythematosus -- The concept of co-stimulatory blockade in SLE -- Cytokines: their role in amplifying SLE pathogenesis -- Intracellular targets in SLE -- Regulatory T cells in SLE -- Balancing strategies: GC and GILZ Axis.

The scope of this contributed volume is to provide an overview of the latest translational research in the field of lupus pathogenesis, with particular emphasis on how these discoveries progress in parallel with therapeutic drug development. Systemic lupus erythematosus (SLE) is a multifaceted disease with a number of well-defined immune pathways that are dysregulated, resulting in an immune-mediated chronic inflammatory injury at target organs. As knowledge of these pathways evolves to provide opportunities for targeted drug therapy and lays the foundation for personalized medicine, clinicians and researchers need to keep up with the ever-expanding medical literature. This book will critically appraise the current understanding of important immunological pathways that contribute to the pathogenesis of lupus. We will review the role of interferons as part of the innate immune defects that perpetuate the loss of self-tolerance in SLE. B cell hyperactivity, as a defining hallmark of SLE, and different strategies of B cell targeted therapy will be discussed. The role of co-stimulation or immune checkpoint molecules in activating B and T cells will be reviewed, as well as other cytokines that serve in the amplification loop promoting a more proinflammatory Th1 or Th17 responses. Intracellular targets, such as signaling molecules in the JAK/STAT pathway, or a variety of kinases and proteasomes, can cause a cascading downstream effect of transcriptional responses that are important in SLE. Immune homeostasis can also be restored by bolstering the naturally occurring anti-inflammatory mechanisms. Glucocorticoid, as a potent natural anti-inflammatory hormone, can mediate its effects by recruiting histone deacetylase that serve to repress gene transcription. Glucocorticoid-induced leucine zipper is a gene upregulated by glucocorticoid that can be a potential target for development of anti-inflammatory strategy. Finally, T regulatory cells can be utilized to help restore to immune tolerance and are amongst the latest focus of therapeutic development in SLE.

ISBN: 9783030851613

Standard No.: 10.1007/978-3-030-85161-3doiSubjects--Topical Terms:

3531188
Systemic lupus erythematosus
--Pathogenesis.

LC Class. No.: RC924.5.L85

Dewey Class. No.: 616.772

National Library of Medicine Call No.: WD 380

Pathogenesis of systemic lupus erythematosus = insights from translational research /
LDR:03768nmm a2200337 a 4500 001 2258591
003 DE-He213
005 20211115124524.0
006 m d
007 cr nn 008maaau
008 220422s2021 sz s 0 eng d
020 $a 9783030851613 $q (electronic bk.)
020 $a 9783030851606 $q (paper)
024 7 $a 10.1007/978-3-030-85161-3 $2 doi
035 $a 978-3-030-85161-3
040 $a GP $c GP
041 0 $a eng
050 4 $a RC924.5.L85
060 4 $a WD 380
072 7 $a MJCM $2 bicssc
072 7 $a MED044000 $2 bisacsh
072 7 $a MJCM $2 thema
082 0 4 $a 616.772 $2 23
090 $a RC924.5.L85 $b P297 2021
245 0 0 $a Pathogenesis of systemic lupus erythematosus $h [electronic resource] : $b insights from translational research / $c edited by Alberta Hoi.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2021.
300 $a xxi, 178 p. : $b ill., digital ; $c 24 cm.
505 0 $a Advances in translational science to identify new therapies for systemic lupus erythematosus -- Hallmark of systemic lupus erythematosus: Role of B Cell Hyperactivity. Fabien B Vincent, William A Figgett and Margaret L Hibbs -- B cell targeted therapies in systemic lupus erythematosus -- Type I Interferons and the perpetuation of a loss of tolerance -- Therapeutic Modulation of the Interferon Pathway in Systemic Lupus Erythematosus -- The concept of co-stimulatory blockade in SLE -- Cytokines: their role in amplifying SLE pathogenesis -- Intracellular targets in SLE -- Regulatory T cells in SLE -- Balancing strategies: GC and GILZ Axis.
520 $a The scope of this contributed volume is to provide an overview of the latest translational research in the field of lupus pathogenesis, with particular emphasis on how these discoveries progress in parallel with therapeutic drug development. Systemic lupus erythematosus (SLE) is a multifaceted disease with a number of well-defined immune pathways that are dysregulated, resulting in an immune-mediated chronic inflammatory injury at target organs. As knowledge of these pathways evolves to provide opportunities for targeted drug therapy and lays the foundation for personalized medicine, clinicians and researchers need to keep up with the ever-expanding medical literature. This book will critically appraise the current understanding of important immunological pathways that contribute to the pathogenesis of lupus. We will review the role of interferons as part of the innate immune defects that perpetuate the loss of self-tolerance in SLE. B cell hyperactivity, as a defining hallmark of SLE, and different strategies of B cell targeted therapy will be discussed. The role of co-stimulation or immune checkpoint molecules in activating B and T cells will be reviewed, as well as other cytokines that serve in the amplification loop promoting a more proinflammatory Th1 or Th17 responses. Intracellular targets, such as signaling molecules in the JAK/STAT pathway, or a variety of kinases and proteasomes, can cause a cascading downstream effect of transcriptional responses that are important in SLE. Immune homeostasis can also be restored by bolstering the naturally occurring anti-inflammatory mechanisms. Glucocorticoid, as a potent natural anti-inflammatory hormone, can mediate its effects by recruiting histone deacetylase that serve to repress gene transcription. Glucocorticoid-induced leucine zipper is a gene upregulated by glucocorticoid that can be a potential target for development of anti-inflammatory strategy. Finally, T regulatory cells can be utilized to help restore to immune tolerance and are amongst the latest focus of therapeutic development in SLE.
650 0 $a Systemic lupus erythematosus $x Pathogenesis. $3 3531188
650 1 4 $a Immunology. $3 611031
650 2 4 $a Molecular Medicine. $3 890952
650 2 4 $a Cytokines and Growth Factors. $3 1084957
700 1 $a Hoi, Alberta. $3 3531187
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
856 4 0 $u https://doi.org/10.1007/978-3-030-85161-3
950 $a Biomedical and Life Sciences (SpringerNature-11642)